Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A. Gavilá J, et al. BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1. BMC Med. 2019. PMID: 30621698 Free PMC article. Clinical Trial.
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J. Codony-Servat J, et al. Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9. Br J Cancer. 2017. PMID: 29123263 Free PMC article.
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B. Marín-Aguilera M, et al. Int J Cancer. 2019 Oct 1;145(7):1970-1981. doi: 10.1002/ijc.32238. Epub 2019 Mar 23. Int J Cancer. 2019. PMID: 30807643
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, Chic N, Puig-Butillé JA, Martínez A, Galván P, Tsai YH, González-Farré B, Mira A, Vivancos A, Villagrasa P, Parker JS, Conte P, Perou CM. Prat A, et al. EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3. EBioMedicine. 2022. PMID: 34990895 Free PMC article.
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domenech M, Figols M, González-Billalabeitia E, Jiménez Peralta D, Rodríguez-Carunchio L, García-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Jiménez N, et al. Cancers (Basel). 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. Cancers (Basel). 2022. PMID: 36230681 Free PMC article.
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar Ín-Aguilera M, Miglietta F, Bottosso M, Giorgi CA, Blasco P, Castillo O, Galv N P, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A. Guarneri V, et al. EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29. EBioMedicine. 2022. PMID: 36374768 Free PMC article. Clinical Trial.
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, Vidal M, Adamo B, Muñoz M, Sanfeliu E, González B, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A, Guarneri V. Brasó-Maristany F, et al. J Natl Cancer Inst. 2023 Mar 9;115(3):332-336. doi: 10.1093/jnci/djac227. J Natl Cancer Inst. 2023. PMID: 36576009 Free PMC article.
45 results